Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 Antibody

Alexander J. Rossi; Tahsin M. Khan; Areeba Saif; Thomas U. Marron; Jonathan M. Hernandez

doi:10.1245/s10434-021-10269-7

Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 Antibody

Alexander J. Rossi
, Tahsin M. Khan
, Areeba Saif
, Thomas U. Marron
, Jonathan M. Hernandez

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English
Pages (from-to)	30-32
Number of pages	3
Journal	Annals of Surgical Oncology
Volume	29
Issue number	1
DOIs	https://doi.org/10.1245/s10434-021-10269-7
State	Published - Jan 2022

Access to Document

10.1245/s10434-021-10269-7

Cite this

@article{b01370753b664e218f4dc3be0d624474,

title = "Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 Antibody",

author = "Rossi, \{Alexander J.\} and Khan, \{Tahsin M.\} and Areeba Saif and Marron, \{Thomas U.\} and Hernandez, \{Jonathan M.\}",

year = "2022",

month = jan,

doi = "10.1245/s10434-021-10269-7",

language = "English",

volume = "29",

pages = "30--32",

journal = "Annals of Surgical Oncology",

issn = "1068-9265",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

TY - JOUR

T1 - Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 Antibody

AU - Rossi, Alexander J.

AU - Khan, Tahsin M.

AU - Saif, Areeba

AU - Marron, Thomas U.

AU - Hernandez, Jonathan M.

PY - 2022/1

Y1 - 2022/1

UR - https://www.scopus.com/pages/publications/85107795725

U2 - 10.1245/s10434-021-10269-7

DO - 10.1245/s10434-021-10269-7

M3 - Letter

C2 - 34117573

AN - SCOPUS:85107795725

SN - 1068-9265

VL - 29

SP - 30

EP - 32

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

IS - 1

ER -